Follicular Lymphoma

Progress in the Treatment of Follicular Lymphoma

April 16, 2020

Follicular Lymphoma

Options for Treating Relapsed/Refractory Follicular Lymphoma

April 03, 2020

Sonali M. Smith, MD, discusses how to handle patients with follicular lymphoma when they relapse, especially if they are early progressors.

Keep Vigilant for Signs of Peripheral Neuropathy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

March 27, 2020

Efficacy analyses by cell of origin and by MYC and BCL2 double expression status showed a trend toward improved outcomes of patients treated on the polatuzumab vedotin-containing arm regardless of cell of origin or MYC and BCL2 doubkle expression status.

Novel Photodynamic Therapy Active in CTCL

March 20, 2020

Treatment with SGX301 led to statistically significant responses in patients with cutaneous T-cell lymphoma, according to preliminary top-line results from the pivotal phase III FLASH trial released by Soligenix.

FDA Partially Halts Phase I Study of ACTR707 in Non-Hodgkin Lymphoma

March 12, 2020

The FDA has placed a partial clinical hold on the phase I trial of ACTR707 in combination with rituximab in patients with relapsed/refractory B-cell lymphoma from Unum Therapeutics, following the submission of a safety report from the company. The FDA notified Unum of the hold verbally on March 4. Unum Therapeutics acknowledged the partial clinical hold in filings with the Securities and Exchange commission.

Careful Data Review Recommended for Upfront Treatment Selection in iNHL

February 29, 2020

To enhance outcomes for patients with indolent non-Hodgkin lymphoma, an in-depth review of the available data is required. As a start, Sonali M. Smith, MD, University of Chicago Medicine, reviewed the clinical trial findings that are currently informing treatment selection in the frontline iNHL paradigm, at 24th Annual International Congress on Hematologic Malignancies.

A 72-Year-Old Man With Symptomatic Follicular Lymphoma

February 27, 2020

A 72-Year-Old Man With Symptomatic Follicular Lymphoma

Early AE Management With Corticosteroids Has Potential to Reduce Rates and Severity of Toxicity With Axi-Cel

February 22, 2020

Evaluation of an expansion cohort of the pivotal phase I/II ZUMA-1 trial in patients with refractory large B-cell lymphoma revealed that early steroid intervention may have a positive impact on the toxicity profile of chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel, according to findings presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.

Investigational Bispecific Antibody Signals Safety and Efficacy in B-Cell NHL

January 14, 2020

In an interview with Targeted Oncology, Rajat Bannerji, MD, PhD, discussed the safety and efficacy findings from the phase I trial of a bispecific antibody in patients with heavily pretreated NHL, including cohorts of patients with follicular lymphoma and diffuse large B-cell lymphoma.

High Rates of CR Observed in Follicular Lymphoma With Triplet Regimen

December 08, 2019

Patients with relapsed/refractory follicular lymphoma showed durable responses with the combination of polatuzumab-vedotin, obinutuzumab, and lenalidomide, according to results presented at the 2019 ASH Annual Meeting.